EUVIMEDEUVIMED entdecken
Multizentrische Studie

Clinical Impact of Skeletal Muscle Mass and Nutritional Status in Patients with Recurrent or Advanced Gastric Cancer Treated with Nivolumab

Qingjiang Hu, Kensuke Kudo, Takafumi Yukaya, Hirofumi Hasuda, Ryota Nakanishi, Tomonori Nakanoko, Koji Ando, Mitsuhiko Ota, Yasue Kimura, Tadashi Koga, Tetsuya Kusumoto, Eiji Oki und 1 weitere

Oncology · 2024

DOI: 10.1159/000540840 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Oncology, 2024. Verfasst von Qingjiang Hu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery and Science, Kyushu University Hospital, Fukuoka, Japan, guitar5158@gmail.com. Hauptthemen laut MEDLINE: Nivolumab, Stomach Neoplasms, Nutritional Status, Muscle, Skeletal. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

This study aimed to evaluate the clinical impact of skeletal muscle mass and nutritional status in gastric cancer patients treated with nivolumab monotherapy as late-line treatment.

Methods

We conducted a multi-institutional retrospective study of 90 gastric cancer patients who previously received anti-PD-1 therapy (nivolumab). On computed tomography images captured before nivolumab induction, the skeletal muscle index (SMI, cm2/m2) was defined as the erector muscle area (cm2) divided by the height (m) squared. Patients were divided into two groups: those with SMI-high (n = 45) and those with SMI-low (n = 45). Prognostic nutritional index (PNI) was also calculated before nivolumab induction. The associations of SMI and PNI with response rate (RR), progression-free survival (PFS), overall survival (OS), disease control rate (DCR), and safety were analyzed.

Results

The cutoff values for SMI were determined as 13.45 for males and 10.41 for females. SMI-high was significantly associated with a higher RR (odds ratio = 12.36, p = 0.02) and DCR (odds ratio = 2.97, p = 0.02). Although not significant, PNI-high also tended to be associated with a higher RR. Multivariate analysis showed that SMI-high was independently associated with a higher RR and higher DCR in gastric cancer. Moreover, prognostic analyses revealed that SMI-high (log-rank test p = 0.008) and PNI-high (log-rank test p = 0.0008) were significantly associated with longer OS since nivolumab induction. SMI-high was also associated with longer PFS (log-rank test p = 0.03). There were no significant differences in immune-related adverse event between SMI-low and SMI-high.

Conclusion

SMI and PNI were associated with nivolumab efficacy in gastric cancer patients. Management of skeletal muscle loss and nutritional status in gastric cancer patients who will receive nivolumab would be beneficial to enhance survival outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NivolumabStomach NeoplasmsNutritional StatusMuscle, SkeletalAntineoplastic Agents, ImmunologicalNeoplasm Recurrence, LocalHumansMaleFemaleMiddle AgedAgedRetrospective StudiesAdultPrognosisAged, 80 and overSarcopeniaProgression-Free Survival

Stichwörter der Autor:innen

Gastric cancerNivolumabNutritional statusSkeletal muscle loss

Substanzen

NivolumabAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Surgery and Science, Kyushu University Hospital, Fukuoka, Japan, guitar5158@gmail.com.
  • Department of Gastroenterological Surgery and Clinical Research Institute Cancer Research Division, National Kyushu Medical Center, Fukuoka, Japan.
  • Department of Surgery, ASO Iizuka Hospital, Iizuka, Japan.
  • Department of Surgery and Science, Kyushu University Hospital, Fukuoka, Japan.

Zitieren

APA

Hu, Q., Kudo, K., Yukaya, T., Hasuda, H., Nakanishi, R., Nakanoko, T., Ando, K., Ota, M., Kimura, Y., Koga, T., Kusumoto, T., Oki, E., & Yoshizumi, T. (2024). Clinical Impact of Skeletal Muscle Mass and Nutritional Status in Patients with Recurrent or Advanced Gastric Cancer Treated with Nivolumab. Oncology. https://doi.org/10.1159/000540840

Vancouver

Hu Q, Kudo K, Yukaya T, Hasuda H, Nakanishi R, Nakanoko T, et al. Clinical Impact of Skeletal Muscle Mass and Nutritional Status in Patients with Recurrent or Advanced Gastric Cancer Treated with Nivolumab. Oncology. 2024. doi:10.1159/000540840

BibTeX
@article{Hu2024,
  author = {Hu, Qingjiang and Kudo, Kensuke and Yukaya, Takafumi and Hasuda, Hirofumi and Nakanishi, Ryota and Nakanoko, Tomonori and Ando, Koji and Ota, Mitsuhiko and Kimura, Yasue and Koga, Tadashi and Kusumoto, Tetsuya and Oki, Eiji and Yoshizumi, Tomoharu},
  title = {Clinical Impact of Skeletal Muscle Mass and Nutritional Status in Patients with Recurrent or Advanced Gastric Cancer Treated with Nivolumab},
  journal = {Oncology},
  year = {2024},
  doi = {10.1159/000540840}
}
Kostenlos starten →